References:
- Kaptoge S, Pennells L, De Bacquer D, Cooney M, Kavousi M, Stevens G et
al. World Health Organization cardiovascular disease risk charts:
revised models to estimate risk in 21 global regions. The Lancet
Global Health. 2019;7(10):e1332-e1345.
- Ference B, Graham I, Tokgozoglu L, Catapano A. Impact of Lipids on
Cardiovascular Health. Journal of the American College of Cardiology.
2018;72(10):1141-1156.
- Yusuf S, Islam S, Chow C, Rangarajan S, Dagenais G, Diaz R et al. Use
of secondary prevention drugs for cardiovascular disease in the
community in high-income, middle-income, and low-income countries (the
PURE Study): a prospective epidemiological survey. The Lancet.
2011;378(9798):1231-1243.
- Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E et al.
Low-density lipoproteins cause atherosclerotic cardiovascular disease.
1. Evidence from genetic, epidemiologic, and clinical studies. A
consensus statement from the European Atherosclerosis Society
Consensus Panel. European Heart Journal. 2017;38(32):2459-2472.
- Anitschkow N, Chalatow S. Classics in arteriosclerosis research: On
experimental cholesterin steatosis and its significance in the origin
of some pathological processes, translated by Mary Z. Pelias, 1913.
Arteriosclerosis: An Official Journal of the American Heart
Association, Inc. 1983;3(2):178-182.
- Müller C. Angina Pectoris in Hereditary Xanthomatosis. Archives of
Internal Medicine. 1939;64(4):675.
- Leary T. Experimental atherosclerosis in the rabbit compared with
human (coronary) atherosclerosis. Arch Path 1934;17:453-492.
- Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps
O et al. Familial hypercholesterolaemia is underdiagnosed and
undertreated in the general population: guidance for clinicians to
prevent coronary heart disease: Consensus Statement of the European
Atherosclerosis Society. European Heart Journal.
2013;34(45):3478-3490.
- Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R.
Blood cholesterol and vascular mortality by age, sex, and blood
pressure: a meta-analysis of individual data from 61 prospective
studies with 55 000 vascular deaths. The Lancet.
2007;370(9602):1829-1839.
- The Emerging Risk Factors Collaboration*, Di Angelantonio E, Sarwar N.
Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA.
2009;302(18):1993.
- Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C,
Blackwell L, Emberson J. Efficacy and safety of more intensive
lowering of LDL cholesterol: a meta-analysis of data from 170 000
participants in 26 randomised trials. The Lancet.
2010;376(9753):1670-1681.
- Holmes M, Asselbergs F, Palmer T, Drenos F, Lanktree M, Nelson C et
al. Mendelian randomization of blood lipids for coronary heart
disease. European Heart Journal. 2014;36(9):539-550. [23, 24]
using ileal bypass [167 doi 10.1093/annone/mdxl 25 Published 13
April 2017.ccessed. ologies and the vailability AN
- Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska K, Mewada A et al.
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein
Cholesterol Beginning Early in Life on the Risk of Coronary Heart
Disease. Journal of the American College of Cardiology.
2012;60(25):2631-2639.
- Stender S, Tybjærg-Hansen A. Using human genetics to predict the
effects and side-effects of drugs. Current Opinion in Lipidology.
2016;27(2):105-111.
- Lipid Research Clinics Program. The Lipid Research Clinics Coronary
Primary Prevention Trial Results. JAMA. 1984;251(3):351.
- Buchwald H, Varco R, Matts J, Long J, Fitch L, Campbell G et al.
Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from
Coronary Heart Disease in Patients with Hypercholesterolemia. New
England Journal of Medicine. 1990;323(14):946-955.
- Boekholdt S, Arsenault B, Mora S, Pedersen T, LaRosa J, Nestel P et
al. Association of LDL Cholesterol, Non–HDL Cholesterol, and
Apolipoprotein B Levels With Risk of Cardiovascular Events Among
Patients Treated With Statins. JAMA. 2012;307(12):1302.
- Cannon C, Blazing M, Giugliano R, McCagg A, White J, Theroux P et al.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New
England Journal of Medicine. 2015;372(25):2387-2397.
- Murín J. [Clinical study FOURIER]. Vnitrni Lekarstvi. 2017;
63(6):411-414.
- Sinnaeve P, Schwartz G, Wojdyla D, Alings M, Bhatt D, Bittner V et al.
Effect of alirocumab on cardiovascular outcomes after acute coronary
syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
European Heart Journal. 2019; ehz809.
- Sabatine M, Giugliano R, Keech A, Honarpour N, Wiviott S, Murphy S et
al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular
Disease. New England Journal of Medicine. 2017;376(18):1713-1722.
- Nicholls S, Puri R, Anderson T, Ballantyne C, Cho L, Kastelein J et
al. Effect of Evolocumab on Progression of Coronary Disease in
Statin-Treated Patients. JAMA. 2016;316(22):2373.
- Lotufo P, Santos R, Figueiredo R, Pereira A, Mill J, Alvim S et al.
Prevalence, awareness, treatment, and control of high low-density
lipoprotein cholesterol in Brazil: Baseline of the Brazilian
Longitudinal Study of Adult Health (ELSA-Brasil). Journal of Clinical
Lipidology. 2016;10(3):568-576.
- Berwanger O, Fonseca H, Pinto I, Izar M, Saraiva F, Fonseca F. PO257
Cardiovascular Risk Management In The Primary Prevention of Patients
Assisted In the Family Health Programs In the Community In Brazil.
Global Heart. 2018;13(4):436.
- Lanas F, Serón P, Lanas A. Coronary Heart Disease and Risk Factors in
Latin America. Global Heart. 2013;8(4):341-348.
- Lanas F, Avezum A, Bautista L, Diaz R, Luna M, Islam S et al. Risk
Factors for Acute Myocardial Infarction in Latin America. Circulation.
2007;115(9):1067-1074.
- Schoj V, Drake I, Moral M, Goldberg L, Begué C, Olalla J et al. 4°
Encuesta Nacional de Factores de Riesgo. Resultados definitivos
[Internet]. Msal.gob.ar. 2018 [cited 25 January 2020].
Available from:
http://www.msal.gob.ar/images/stories/bes/graficos/0000001622cnt-2019-10_4ta-encuesta-nacional-factores-riesgo.pdf
- Mehta R, Zubirán R, Martagón A, Vazquez-Cárdenas A, Segura-Kato Y,
Tusié-Luna M et al. The panorama of familial hypercholesterolemia in
Latin America: a systematic review. Journal of Lipid Research.
2016;57(12):2115-2129.
- Wilemon K, Patel J, Aguilar-Salinas C, Ahmed C, Alkhnifsawi M,
Almahmeed W et al. Reducing the Clinical and Public Health Burden of
Familial Hypercholesterolemia. JAMA Cardiology. 2020; [Epub ahead of
print].
- Watts G, Gidding S, Mata P, Pang J, Sullivan D, Yamashita S et al.
Familial hypercholesterolaemia: evolving knowledge for designing
adaptive models of care. Nature Reviews Cardiology. 2020; [Epub
ahead of print].
- Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E et al.
Comparison of the efficacy and safety of rosuvastatin versus
atorvastatin, simvastatin, and pravastatin across doses (STELLAR*
Trial). The American Journal of Cardiology. 2003;92(2):152-160.
- Taylor F, Huffman M, Ebrahim S. Statin Therapy for Primary Prevention
of Cardiovascular Disease. JAMA. 2013;310(22):2451.
- Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B et
al. Efficacy of statins for primary prevention in people at low
cardiovascular risk: a meta-analysis. Canadian Medical Association
Journal. 2011;183(16):E1189-E1202.
- Cholesterol Treatment Trialists (CTT) Collaborators, Mihaylova B,
Emberson J, Blackwell L, Keech A, Simes J. The effects of lowering LDL
cholesterol with statin therapy in people at low risk of vascular
disease: meta-analysis of individual data from 27 randomised trials.
The Lancet. 2012;380(9841):581-590.
- Cholesterol Treatment Trialists (CTT) Collaborators, Kearney P,
Blackwell L, Collins R, Keech A, Simes J. Efficacy of
cholesterol-lowering therapy in 18 686 people with diabetes in 14
randomised trials of statins: a meta-analysis. The Lancet.
2008;371(9607):117-125.
- Cholesterol Treatment Trialists (CTT) Collaborators, Armitage J,
Baigent C, Barnes E, Betteridge D, Blackwell L et al. Efficacy and
safety of statin therapy in older people: a meta-analysis of
individual participant data from 28 randomised controlled trials. The
Lancet. 2019;393(10170):407-415.
- Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of
discontinuing statins for primary prevention at the age of 75 years: a
nationwide population-based cohort study in France. European Heart
Journal. 2019;40(43):3516-3525.
- Stroes E, Thompson P, Corsini A, Vladutiu G, Raal F, Ray K et al.
Statin-associated muscle symptoms: impact on statin therapy—European
Atherosclerosis Society Consensus Panel Statement on Assessment,
Aetiology and Management. European Heart Journal.
2015;36(17):1012-1022.
- Ridker P, Pradhan A, MacFadyen J, Libby P, Glynn R. Cardiovascular
Benefits and Diabetes Risks of Statin Therapy in Primary Prevention:
An Analysis From the JUPITER Trial. Journal of Vascular Surgery.
2012;56(6):1809.
- Preiss D, Seshasai S, Welsh P, Murphy S, Ho J et al. Risk of Incident
Diabetes With Intensive-Dose Compared With Moderate-Dose Statin
Therapy. JAMA. 2011;305(24):2556.
- Davis H, Tershakovec A, Tomassini J, Musliner T. Intestinal sterol
transporters and cholesterol absorption inhibition. Current Opinion in
Lipidology. 2011;22(6):467-478.
- Phan B, Dayspring T, Toth P. Ezetimibe therapy: mechanism of action
and clinical update. Vascular Health and Risk Management.
2012;8:415-427.
- Morrone D, Weintraub W, Toth P, Hanson M, Lowe R, Lin J et al.
Lipid-altering efficacy of ezetimibe plus statin and statin
monotherapy and identification of factors associated with treatment
response: A pooled analysis of over 21,000 subjects from 27 clinical
trials. Atherosclerosis. 2012;223(2):251-261.
- Lambert G, Sjouke B, Choque B, Kastelein J, Hovingh G. The PCSK9
decade. Journal of Lipid Research. 2012;53(12):2515-2524.
- Seidah N, Prat A. The biology and therapeutic targeting of the
proprotein convertases. Nature Reviews Drug Discovery.
2012;11(5):367-383.
- Lipinski M, Benedetto U, Escarcega R, Biondi-Zoccai G, Lhermusier T,
Baker N et al. The impact of proprotein convertase subtilisin-kexin
type 9 serine protease inhibitors on lipid levels and outcomes in
patients with primary hypercholesterolaemia: a network meta-analysis.
European Heart Journal. 2015;37(6):536-545.
- Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A et al.
2016 European Guidelines on cardiovascular disease prevention in
clinical practice. European Heart Journal. 2016;37(29):2315-2381.
- Schwartz G, Steg P, Szarek M, Bhatt D, Bittner V, Diaz R et al.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
New England Journal of Medicine. 2018;379(22):2097-2107.
- Précoma D, Oliveira G, Simão A, Dutra O, Coelho-Filho O, Izar M et al.
Updated Cardiovascular Prevention Guideline of the Brazilian Society
of Cardiology - 2019. Arquivos Brasileiros de Cardiologia. 2019;113(4)
Epub.
- Herdy A, López-Jiménez F, Terzic C, Milani M, Stein R, Carvalho T et
al. South American Guidelines for Cardiovascular Disease Prevention
and Rehabilitation. Arquivos Brasileiros de Cardiologia. 2014;103(2).
- Malachias M. Apresentação. Arquivos Brasileiros de Cardiologia.
2016;107(3).
- Faludi A, Izar M, Saraiva J, Chacra A, Bianco H, Afiune Neto A et al.
Atualização da diretriz brasileira de dislipidemias e prevenção da
aterosclerose - 2017. Arquivos Brasileiros de Cardiologia.
2017;109(1).
- Pavía AA, Aguilar C. (in press). Consenso de la sociedad mexicana de
cardiología y tratamiento de las dislipidemias y ateroesclerosis.
Diabetes Hoy.
- Stone N, Robinson J, Lichtenstein A, Bairey Merz C, Blum C, Eckel R et
al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to
Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation.
2013;129(25 suppl 2):S1-S45.
- Reiner Z, Catapano A, De Backer G, Graham I, Taskinen M, Wiklund O et
al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task
Force for the management of dyslipidaemias of the European Society of
Cardiology (ESC) and the European Atherosclerosis Society (EAS).
European Heart Journal. 2011;32(14):1769-1818.
- Hernández S, de Zarate M, Torres Arreola L. Diagnóstico y tratamiento
de Dislipidemias (Hipercolesterolemia) en el adulto. Colonia Juárez,
Mexico: Instituto Mexicano del Seguro Social; 2016.
- Avezum A, Oliveira G, Lanas F, Lopez-Jaramillo P, Diaz R, Miranda J et
al. Secondary CV Prevention in South America in a Community Setting.
Global Heart. 2017;12(4):305-313.
- Murphy A, Palafox B, O’Donnell O, Stuckler D, Perel P, AlHabib K et
al. Inequalities in the use of secondary prevention of cardiovascular
disease by socioeconomic status: evidence from the PURE observational
study. The Lancet Global Health. 2018;6(3):e292-e301.
- Fonseca HAR, Fonseca FA, Pinto IM, Izar MC, Saraiva JF, Berwanger O.
Adultos brasileiros que demonstram controle da hipertensão arterial e
da diabetes tipo 2 apresentam um controle ineficiente da dislipidemias
nas comunidades. Arq Bras Cardiol 2019 113(2 supl.2): 23.
- Saraiva J, Cordeiro Mattos A, Saraiva G, Pinto I, Rombaldi A, Kato N
et al. P6444Cardiovascular secondary prevention setting and lipid
controlu, update data from PINNACLE BRAZIL REGISTRY. European Heart
Journal. 2019;40(Supplement_1).
- Báscolo E, Houghton N, Del Riego A. Lógicas de transformación de los
sistemas de salud en América Latina y resultados en acceso y cobertura
de salud. Revista Panamericana de Salud Pública. 2018;42(e126).
- Bustamante A, Mendez C. Health Care Privatization in Latin America:
Comparing Divergent Privatization Approaches in Chile, Colombia, and
Mexico. Journal of Health Politics, Policy and Law.
2014;39(4):841-886.
- Healthcare in Latin America and the Caribbean: a democratic challenge
[Internet]. openDemocracy. 2016 [cited 26 January 2020].
Available from:
https://www.opendemocracy.net/en/democraciaabierta/healthcare-in-latin-america-and-caribbean-democratic-ch/
- Atun R, de Andrade L, Almeida G, Cotlear D, Dmytraczenko T, Frenz P et
al. Health-system reform and universal health coverage in Latin
America. The Lancet. 2015;385(9974):1230-1247.
- Rasella D, Harhay M, Pamponet M, Aquino R, Barreto M. Impact of
primary health care on mortality from heart and cerebrovascular
diseases in Brazil: a nationwide analysis of longitudinal data. BMJ.
2014;349(jul03 5):g4014-g4014.
- Salud en las Américas (Resumen: panorama regional y perfiles de país),
2017 Edition [Internet]. Washington, DC: Organización Panamericana
de la Salud; 2017 [cited 26 January 2020]. Available from:
https://www.paho.org/salud-en-las-americas-2017/wp-content/uploads/2017/09/Print-Version-Spanish.pdf
- Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K et al.
Availability and affordability of cardiovascular disease medicines and
their effect on use in high-income, middle-income, and low-income
countries: an analysis of the PURE study data. The Lancet.
2016;387(10013):61-69.
- Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O et al.
The availability and affordability of selected essential medicines for
chronic diseases in six low- and middle-income countries. Bulletin of
the World Health Organization. 2007;85(4):279-288.
- Cunha Garcia G, Rodrigues T. Boletim Saúde e Economia nº 6 (Versão
1.2). Brasilia, Brazil: ANVISA; 2011.
- Ribeiro R, Duncan B, Ziegelmann P, Stella S, Vieira J, Restelatto L et
al. Cost-Effectiveness of High, Moderate and Low-Dose Statins in the
Prevention of Vascular Events in the Brazilian Public Health System.
Arquivos Brasileiros de Cardiologia. 2014;104(1):32-43.
- Vargas-Pelaez C, Rover M, Soares L, Blatt C, Mantel-Teeuwisse A, Rossi
F et al. Judicialization of access to medicines in four Latin American
countries: a comparative qualitative analysis. International Journal
for Equity in Health. 2019;18(1).
- Mitchell A, Simpson R. Statin cost effectiveness in primary
prevention: A systematic review of the recent cost-effectiveness
literature in the United States. BMC Research Notes. 2012;5:373.
- Annemans L, Packard C, Briggs A, Ray K. ‘Highest risk–highest
benefit’ strategy: a pragmatic, cost-effective approach to targeting
use of PCSK9 inhibitor therapies. European Heart Journal.
2017;39(27):2546-2550.
- José Gagliardino J, Arechavaleta R, Goldberg Eliaschewitz F, Iglay K,
Brodovicz K, Gonzalez C et al. Dyslipidemia: The untreated metabolic
dysfunction in people with type 2 diabetes in Latin America. ARETAEUS
study outcomes. Journal of Clinical & Translational Endocrinology.
2019;15:76-80.
- Programa Farmácia Popular [Internet]. Ministry of Health Brasil.
2013 [cited 28 November 2019]. Available from:
http://www.saude.gov.br/acoes-e-programas/farmacia-popular
- Araújo L, Albuquerque K, Kato K, Silveira G, Maciel N, Spósito P et
al. Medicamentos genéricos no Brasil: panorama histórico e legislação.
Revista Panamericana de Salud Pública. 2010;28(6):480-492.
- Kishore S, Blank E, Heller D, Patel A, Peters A, Price M et al.
Modernizing the World Health Organization List of Essential Medicines
for Preventing and Controlling Cardiovascular Diseases. Journal of the
American College of Cardiology. 2018;71(5):564-574.
- Años de vida perdidos [Internet]. Organización Panamericana de la
Salud. [cited 12 October 2019]. Available
from: https://hiss.paho.org/pahosys/pyll.php
- Rivera-Andrade A, Luna M. Trends and Heterogeneity of Cardiovascular
Disease and Risk Factors Across Latin American and Caribbean
Countries. Progress in Cardiovascular Diseases. 2014;57(3):276-285.